NR1H4 and Cirrhosis: A phase 2 trial is currently evaluating semaglutide, both alone and combined with a fixed dose of cilofexor, a nonsteroidal farnesoid X receptor (FXR) agonist, and firsocostat, a liver-targeted acetyl-CoA carboxylase (ACC) inhibitor, in patients with compensated MASH-related cirrhosis [177].